Carmell Corporation (CTCX)
NASDAQ: CTCX · Real-Time Price · USD
0.240
-0.006 (-2.28%)
Nov 21, 2024, 12:28 PM EST - Market open

Company Description

Carmell Corporation operates as a bio-aesthetics company.

The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks.

The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

In addition, the company is also developing a line of men’s products and a line of topical haircare products.

It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics.

The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023.

Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

Carmell Corporation
Carmell logo
Country United States
Founded 2007
Industry Household & Personal Products
Sector Consumer Staples
Employees 10
CEO Kendra Bracken-Ferguson

Contact Details

Address:
2403 Sidney Street, Suite 300
Pittsburgh, Pennsylvania 15203
United States
Phone 919 313 9633
Website carmellcosmetics.com

Stock Details

Ticker Symbol CTCX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001842939
CUSIP Number 142922103
ISIN Number US1429221039
Employer ID 86-1645738
SIC Code 3841

Key Executives

Name Position
Kendra Bracken-Ferguson Chief Executive Officer
Rajiv Sarman Shukla Executive Chairman
Bryan J. Cassaday Chief Financial Officer
Dr. Phil Campbell Ph.D. Founder and Chief Scientific Officer
Dr. Lee Weiss Ph.D. Founder
Dr. James Burgess M.D. Founder

Latest SEC Filings

Date Type Title
Nov 20, 2024 8-K Current Report
Nov 19, 2024 S-8 Securities to be offered to employees in employee benefit plans
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 424B3 Prospectus
Nov 14, 2024 10-Q Quarterly Report
Oct 15, 2024 RW Filing
Oct 3, 2024 424B3 Prospectus
Oct 3, 2024 8-K Current Report
Aug 30, 2024 424B3 Prospectus
Aug 30, 2024 8-K Current Report